Edwin Astudillo

Edwin Astudillo is a partner in the Corporate Practice Group in the firm's San Diego (Del Mar) office. 

Areas of Practice
Edwin’s practice focuses on advising companies in SEC reporting matters, capital raising transactions, and mergers and acquisitions, including going private transactions and mergers involving public companies. He advises companies in a variety of industries including companies in the biotech, medical device, and information technology industries.

Edwin assists clients in financing their business through private placements and public offerings. He regularly counsels publicly traded companies in SEC reporting and corporate governance matters, and stock exchange and securities laws compliance. Edwin works with business owners and management on legal issues that arise in the operation of their business on a daily basis.  He has represented clients in transactions ranging from the sale of a family-held business to the sale of a NYSE-listed company in a deal that was recognized by China Business Law Journal as the Going Private Deal of the Year.

Experience

Capital Markets and Related Matters

• Represented public companies in registered direct, CMPO, ATM and PIPE offerings involving equity and debt securities
• Represented investors in recapitalization of a public company
• Represented issuer in AIM listing application and public offering
• Represented financial institutions in their initial public offerings
• Represented a non-profit-sponsored community asset-building entity in its initial public offering
• Represented placement agents in secondary public and private offerings
• Represented private companies in debt and equity offerings

M&A Transactions

• Represented NTN Buzztime, Inc. (NYSE MKT) in simultaneous asset sale and reverse merger transaction
• Represented Daré Bioscience, Inc. (Nasdaq) in its acquisition of a privately-held drug delivery technology company
• Represented a privately-held medical device company in its acquisition by Therabody
• Represented a privately-held artificial intelligence, sales pipeline management, and forecasting company in its acquisition by subsidiary of Vista Equity Partners
• Represented acquiror in going-private transaction of Acorn International, Inc. (NYSE)
• Represented the special committee of the board of directors of Physicians Formula Holdings, Inc. (Nasdaq) in a going-private transaction
• Represented CACI International Inc (NYSE) in its acquisition of Paradigm Holdings, Inc. (OTC: PDHO)
• Represented a private equity group in going-private transaction of Playboy Enterprises, Inc. (NYSE)
• Represented the special committee of the board of directors of Tongjitang Chinese Medicines (NYSE) in a going-private transaction
• Represented the special committee of the board of directors of Pomeroy IT Solutions (NASDAQ) in going-private transaction
• Represented a privately-held solid-state technology company in sale to a global consumer electronic company
• Represented a social interactive entertainment company in strategic acquisitions
• Represented a construction management company in stock sale
• Represented a agriculture company in stock sale
• Represented a public shell in a reverse merger with a Korean mobile advertising company
• Represented a privately-held developer of platforms for web-based applications in a reverse merger with a public shell
• Represented a public bank holding company in acquisition of multiple branches
• Represented a public company in acquisition of privately-held VoIP company
• Represented an apparel wholesaler in the strategic acquisition of a privately-held outdoor lifestyle retailer
• Represented various closely-held businesses in employee buy-in transactions and restructurings
• Represented a privately held outdoor consumer good company in $35M stock sale
• Represented a national bank in a merger with another national bank
• Represented a private individual in the acquisition of a regional petroleum distribution company
• Represented the seller of a dry underground utilities engineering company to a private equity firm
• Represented a state-chartered bank in a merger with a bank holding company
• Represented a national bank in a going private transaction
• Represented a US company in the acquisition of a Mexican maquiladora operation

Honors

Best Lawyers in America, Best Lawyers, 2024-2025

Articles

Corporate & Securities Law Blog Posts

• "Revised Schedule 13g Filing Deadlines Effective as of September 30, 2024 – What You Need to Know," October 1, 2024

• "SEC Updates Non-GAAP Financial Measures Guidance," January 4, 2023